Rostec and Marathon Group merge their pharmaceutical assets

| By | Nacimbio, Pharmaceutical Deal, Rostec

Sergey Chemezov, CEO of Rostec Corporation, and Alexander Vinokurov, President of Marathon Group, an investment company, agreed to merge their pharmaceutical assets to establish a federal-level manufacturer and supplier of pharmaceutical products. This agreement is an example of public-private partnership and aims at attracting additional technological competencies and investments to develop the key areas of Russian pharmacology.

The merged company will include the enterprises of Nacimbio (a part of Rostec Corporation), and distribution and production assets of Marathon Group, such as, SIA Group, one of the largest Russian distributors. Nacimbio is expected to act as a corporate platform; other significant parameters will be determined during the assessment of assets and structuring of the deal. The deal is set to be closed before the end of this year.

The activities of the new pharmaceutical company will be aimed at further implementation of Rostec strategy to ensure the national biological security. The unified business will focus on developing and manufacturing the innovative Russian-made medicinal products, and serve as a basis to establish a national pharmaceutical distributor.

Rostec and Marathon Group already have the experience of fruitful cooperation, as the two companies are implementing a number of joint projects based on Sintez and Fort plants.

GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.